Skip to main content

Advertisement

Table 1 Clinical and laboratory data at baseline and 3 and 6 months of follow-up

From: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

Variables Baseline Follow up (90 days) Follow up (180 days) p value
  80.78 ± 15.91 79.98 ± 14.98 80.52 ± 15.63 0.12
BMI (kg/m2) 31.18 ± 5.42 30.85 ± 5.09 31.03 ± 5.17 0.82
WHR (cm) 101.77 ± 11.24 100.67 ± 10.21 100.53 ± 10.71 0.12
HbA1c (%) 7.61 ± 1.53 7.58 ± 1.44 7.68 ± 1.50 0.713
Cholesterol (mg/dl) 189.33 ± 40.78 191.17 ± 38.39 190.03 ± 42.12 0.945
Triglycerides (mg/dl) 142.53 ± 75.12 186.17 ± 162.79 185.28 ± 139.27 0.088
LDL Chol (mg/dl) 114.59 ± 32.93 109.50 ± 31.18 109.19 ± 33.78 0.463
HDL Chol (mg/dl) 48.51 ± 10.39 48.83 ± 9.07 46.89 ± 10.24 0.242
Vitamin B12 (pg/dl) 293.91 ± 126.54 287.46 ± 122.65 291.57 ± 132.26 0.844
CRP (mg/dl) 0.352 ± 0.31 0.431 ± 0.28 0.372 ± 0.35 0.327
AER (mg/min) 21.04 ± 53.24 27.44 ± 77.76 27.36 ± 75.76 0.309
  1. Data are presented as means ± standard deviation.
  2. Abbreviations: BMI: Body mass index; WHR: Waist/hip ratio;
  3. HbA1C: glycated haemoglobin; CRP: C-reactive protein; AER: Albumin Excretion rate